Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer.

Abstract

BACKGROUND:

We report the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.

MATERIALS AND METHODS:

We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods.

RESULTS:

Sixty-five patients were identified with median age of 71 years (range 44-85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m2 , respectively. At a median follow-up of 29 (range 5-91) months, the 2-year rates of LRR, DM, PFS, and OS were 8.8%, 9.4%, 72.2%, and 88.7%, respectively. In total, there were 5 LRR, 7 DM, and 12 deaths.

CONCLUSIONS:

Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin-ineligible HNSCC patients.

• Authors: James Han, Kaveh Zakeri, Gabriel Raab, Jennifer Hesse, Achraf Shamseddine, Linda Chen, Yao Yu, Jung Julie Kang, Sean M McBride, Nadeem Riaz, C Jillian Tsai, Daphna Gelblum, Eric J Sherman, Richard J Wong, Loren Michel, Nancy Y Lee
• Journal: Head & neck (Head Neck) Vol. 45 Issue 9 Pg. 2207-2216 (09 2023) ISSN: 1097-0347 [Electronic] United States
• PMID: 37439286 (Publication Type: Journal Article)
• Copyright: © 2023 Wiley Periodicals LLC.

Chemical References

• Carboplatin
• Paclitaxel
• Cisplatin

Topics

• Humans
• Adult
• Middle Aged
• Aged
• Aged, 80 and over
• Carboplatin (therapeutic use)
• Paclitaxel
• Cisplatin (therapeutic use)
• Squamous Cell Carcinoma of Head and Neck (drug therapy)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Neoplasm Recurrence, Local (drug therapy)
• Head and Neck Neoplasms (drug therapy)
• Chemoradiotherapy (adverse effects)